Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by August 25, 2025, to serve as lead plaintiff [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy [4] - Specific claims include that Hims failed to disclose the nature of its collaboration with Novo and the offerings of compounded semaglutide products [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages [4]

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding its business practices and partnerships, particularly concerning the promotion of Wegovy® and its collaboration with Novo Nordisk [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Hims securities between April 29, 2025, and June 23, 2025, with a deadline of August 25, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy®, which posed risks to patient safety [3]. - It is claimed that the company's positive statements about its business and prospects were materially misleading due to undisclosed risks regarding its collaboration with Novo Nordisk [3][4]. Group 2: Allegations Against Hims - The complaint specifies that Hims failed to disclose that its communication with Novo Nordisk was not as beneficial as portrayed, potentially jeopardizing the long-term collaboration for access to Wegovy [4]. - It is alleged that Hims misrepresented the approval of its compounded semaglutide products by Novo Nordisk, which could mislead investors about the company's product offerings [4]. - The lawsuit highlights that Hims made positive statements about its partnership with Novo, which were not supported by the actual circumstances surrounding the collaboration [4].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements and the promotion of illegitimate products [1][2][3] Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk A/S on April 29, 2025, to sell a bundled offering of Wegovy® [2] Allegations and Impact - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2][3] - Novo Nordisk terminated its partnership with Hims & Hers on June 23, 2025, due to these deceptive practices, leading to a stock price drop of over 34% [3] Legal Process - Investors who purchased Hims & Hers securities during the class period (April 29, 2025, to June 23, 2025) can seek to be appointed as lead plaintiff in the lawsuit [4] - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [4] Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 [5]

Group 1 - The core viewpoint is that Hims & Hers is transitioning from being perceived merely as a telemedicine company to a comprehensive, data-driven precision health platform with software-like economics and predictable recurring revenue [1] - The company is experiencing increasing operating leverage, which indicates a potential for higher profitability as it scales [1] - The narrative surrounding Hims & Hers is often misunderstood, with the market not fully pricing in its long-term potential and scalable business model [1] Group 2 - The investment approach emphasizes a fundamental, bottom-up strategy focusing on market psychology, business durability, and valuation discipline [1] - The company is particularly appealing due to its scalable models and durable competitive advantages, which are often overlooked by investors [1] - The investment philosophy highlights the nonlinear nature of investing success, shaped by cycles and constant recalibration [1]

Core Viewpoint - Hims & Hers Health (NYSE: HIMS) faces significant challenges following a drop in share price due to an FTC investigation into its advertising practices and the termination of a collaboration with Novo Nordisk, which raised safety concerns regarding its weight-loss drug offerings [1][2][5]. Group 1: Company Challenges - The share price of Hims & Hers dropped significantly in after-hours trading after reports of an FTC probe into its advertising practices and subscription cancellation difficulties [1]. - Novo Nordisk ended its collaboration with Hims, citing serious accusations that Hims was jeopardizing patient safety, which has led to a pending securities class action lawsuit against the company [2][4]. - Following the termination of the partnership, Hims' stock price fell more than 34% on June 23, 2025 [5]. Group 2: Financial Performance - Hims reported total revenue of $545 million for Q2 2025, reflecting a 7% sequential decline [6]. - Revenue from compounded GLP-1 weight-loss drugs decreased to $190 million from $230 million in the previous quarter [6]. - The revenue per subscriber fell to $74 from $84, attributed to the off-boarding of some GLP-1 subscribers [6]. Group 3: Legal and Regulatory Issues - A class action complaint alleges that Hims made false and misleading statements regarding its promotion of illegitimate versions of Wegovy, which posed safety risks to patients [4]. - Hagens Berman is investigating claims from investors who suffered substantial losses during the class period from April 29, 2025, to June 23, 2025, with a lead plaintiff deadline of August 25, 2025 [3][7].

Core Viewpoint - A class action securities lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud that negatively impacted investors between April 29, 2025, and June 23, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Hims & Hers Health, Inc. engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2]. - It is alleged that this misconduct posed a significant risk of terminating the Company's collaboration with Novo Nordisk [2]. - The defendants' positive statements regarding the Company's business and prospects are claimed to be materially misleading and lacking a reasonable basis due to the aforementioned issues [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be eligible for compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Hims & Hers Health Inc. is facing potential securities fraud claims following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and selling unapproved products [2][3] Group 1: Legal Investigation - Berger Montague is investigating Hims & Hers for potential securities fraud claims, particularly regarding misleading statements made during the Class Period from April 29, 2025, to June 22, 2025 [1][3] - Investors who acquired Hims & Hers securities during the Class Period have until August 25, 2025, to seek appointment as lead plaintiff representatives [1] Group 2: Partnership Termination - Novo Nordisk announced the termination of its partnership with Hims & Hers on June 23, 2025, citing deceptive marketing practices and the sale of unapproved compounded versions of semaglutide [2] - Following the announcement, Hims & Hers shares dropped over 34% in intraday trading, indicating significant investor concern regarding regulatory compliance and reputational risks [2] Group 3: Allegations of Misleading Statements - The lawsuit alleges that Hims & Hers made materially false or misleading statements about the nature and regulatory status of its GLP-1 offerings and the risks associated with its partnership with Novo Nordisk [3] - The investigation is focused on whether Hims & Hers and certain executives violated federal securities laws by providing false or misleading information to investors [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 25, 2025 [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has consistently ranked in the top 4 for securities class action settlements since 2013, recovering hundreds of millions for investors [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, affecting investor decisions [4] - Specific claims include the failure to disclose the nature of the collaboration with Novo and the implications for Hims subscribers' access to the weight-loss drug Wegovy [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages [4]

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of a weight loss drug, which has resulted in a significant drop in its stock price following the termination of a partnership with Novo Nordisk [1][4][5]. Group 1: Company Overview - Hims & Hers Health is a telehealth company that offers prescription and over-the-counter medications, as well as personal care products [3]. Group 2: Legal Allegations - The class action lawsuit claims that during the class period from April 29, 2025, to June 23, 2025, Hims & Hers made false or misleading statements and failed to disclose material facts regarding its business practices [4]. - Specific allegations include the deceptive promotion and sale of illegitimate versions of Novo Nordisk's weight loss drug, Wegovy®, which posed risks to patient safety [4]. - The lawsuit also suggests that these actions led to a significant risk of termination of the collaboration with Novo Nordisk [4]. Group 3: Impact of the Lawsuit - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers, citing the deceptive practices as the reason, which resulted in a more than 34% decline in Hims & Hers' stock price [5].

Core Viewpoint - Securities class action lawsuits have been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding the company's business practices and operations during the specified class period [1][2]. Group 1: Allegations Against Hims & Hers - The complaints allege that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy, which posed risks to patient safety [2]. - It is claimed that there was a substantial risk of termination of Hims & Hers' collaboration with Novo Nordisk due to these practices [2]. - The positive statements made by the defendants about the company's business and prospects were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors in Hims & Hers have until August 25, 2025, to seek appointment as lead plaintiff representatives in the class action [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3]. - Participation as a lead plaintiff does not affect the ability of other investors to share in any recovery from the lawsuit [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm aims to protect investors and consumers from fraud and negligence by businesses [4].